Core Viewpoint - The overall performance of the company is steadily growing, with laboratory services and CMC services contributing the main incremental growth [2] Group 1: Financial Performance - The revenue from large multinational clients has significantly increased, indicating a positive trend in demand [2] - There is a noticeable recovery in demand from Chinese clients, suggesting a potential market rebound [2] Group 2: Industry Context - The company faces risks related to geopolitical uncertainties and tariffs, which could impact future performance [2] - The investment and financing in the biopharmaceutical industry are below expectations, posing a challenge for growth [2] - The competitive landscape in the industry is intensifying, which may affect market positioning [2]